Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 21st International Workshop on Non-Hodgkin Lymphoma (iwNHL) took place in Nice, France, on 19 - 21 September, 2024. Esteemed experts convened to discuss the latest research findings in non-Hodgkin lymphoma and strategies to enhance patient outcomes.
iwNHL 2024
21st International Workshop on Non-Hodgkin Lymphoma
19–21 September 2024 | Nice, France
The 21st International Workshop on Non-Hodgkin Lymphoma (iwNHL) took place in Nice, France, on 19 - 21 September, 2024. Esteemed experts convened to discuss the latest research findings in non-Hodgkin lymphoma and strategies to enhance patient outcomes.
Explore roundtable discussions from this year's workshop
View all videos
Session 1: T-cell leukemia/lymphoma
LGL leukemia – current treatments and perspectives
Thierry Lamy Rennes University Hospital, Rennes, France
Epigenetic changes in T-PLL and mature T-cell lymphomas
Reiner Siebert Ulm University, Ulm, Germany
Coming soon!
Current and future treatment approaches in T-cell lymphoma
Francine Foss Yale School of Medicine, New Haven, CT, United States
Coming soon!
AUTO4 (TRBC1-directed autologous CAR-T) in TRBC1-positive PTCL
Kate Cwynarski University College Hospital, London, United Kingdom
Session 2: Evolving frontline immune-chemotherapy for MCL
Under the microscope – prognostic and predictive markers in MCL
Rebecca King Mayo Clinic, Rochester, MN, United States
Has frontline therapy for MCL changed from intensive chemo-based to targeted small molecule-based?
John Kuruvilla Princess Margaret Cancer Centre, Toronto, Canada
Has maintenance therapy replaced ASCT in MCL?
Michael Williams The University of Virginia School of Medicine, Charlottesville, VA, United States
New strategies to manage relapsed MCL
Caron Jacobson Dana-Farber Cancer Institute, Boston, MA, United States
Session 3: Keynote address
Modelling the crosstalk between malignant B-cells and their microenvironment in B-cell lymphomas: challenges and opportunities
Karin Tarte CHU Rennes, Rennes, France
Coming soon!
Session 4: Novel therapies – ADCs
Polatuzumab vedotin
Laurie Sehn BC Cancer Agency, Vancouver, Canada
Zilovertamab vedotin
Sven de Vos David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
Loncastuximab tesirine
Paolo Caimi Cleveland Clinic, Cleveland, OH, United States
Emerging ADCs with novel targets
Juan Alderuccio Sylvester Comprehensive Cancer Center, Miami, FL, United States
Brentuximab vedotin in DLBCL
Alex Herrera City of Hope, Duarte, CA, United States
Session 5: Expanding the CAR platform for NHL
Tisa-cel & rapcabtagene
Jason Westin The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon!
Axi-cel
Sattva Neelapu The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Liso-cel
David Maloney Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Coming soon!
Optimizing NHL therapy with novel CAR-T platforms
John Gerecitano Sana Biotechnology, Seattle, WA, United States
Coming soon!
CB-010
Stephen Schuster Perelman School of Medicine, Philadelphia, PA, United States
Coming soon!
Development of CAR-T platforms for T-cell lymphomas
LaQuisa Hill Baylor College of Medicine, Houston, TX, United States
CAR-T vs auto-HCT in first relapse – is auto-HCT dead?
Jason Westin The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon!
Strategies to minimize toxicity of CAR T-cell treatment
Caron Jacobson Dana-Farber Cancer Institute, Boston, MA, United States
Allogeneic CAR T-cells: Is there a strategy moving forward?
Catherine Bollard Children's National Research Institute, Washington, WA, United States
CAR-T for CLL. Where do we stand? Who and when do we treat?
Tanya Siddiqi City of Hope, Duarte, CA, United States
Session 6: Special Topic
The germinal center in the pathogenesis of B-cell lymphomas
Laura Pasqualucci Columbia University, New York City, NY, United States
Coming soon!
Session 7: Novel therapies
BTK inhibitors
Is there still a role for ibrutinib?
Alexey Danilov City of Hope, Duarte, CA, United States
Zanubrutinib
Pier L. Zinzani University of Bologna, Bologna, Italy
Coming soon!
Acalabrutinib
Stephen Ansell Mayo Clinic, Rochester, MN, United States
Pirtobrutinib
Krish Patel Sarah Cannon Research Institute, Nashville, TN, United States
BTK degraders
NX-2127 & NX-5948
Alexey Danilov City of Hope, Duarte, CA, United States
Coming soon!
BGB-16673
Michael Wang The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon!
BCL-2 inhibitors
Sonrotoclax (BGB-11417)
Michael Wang The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon!
Novel venetoclax combinations
Tanya Siddiqi City of Hope, Duarte, CA, United States
ViPOR regimen in DLBCL
Jordan Goldstein Stanford University, Stanford, CA, United States
Session 8: Bispecific antibodies for NHL
Glofitamab
Martin Hutchings Copenhagen University Hospital, Copenhagen, Denmark
Mosunetuzumab
Krish Patel Sarah Cannon Research Institute, Nashville, TN, United States
Odronextamab
Stephen Ansell Mayo Clinic, Rochester, MN, United States
Epcoritamab
Martin Hutchings Copenhagen University Hospital, Copenhagen, Denmark
TNB 486
Pier L. Zinzani University of Bologna, Bologna, Italy
Coming soon!
Other bi-and trispecific antibodies in early development
Marion Subklewe LMU Hospital Munich, Munich, Germany
iwNHL 2024 has been supported by:
